Information Provided By:
Fly News Breaks for December 5, 2019
PTCT
Dec 5, 2019 | 07:10 EDT
RBC Capital analyst Brian Abrahams raised his price target on PTC Therapeutics to $58 and kept his Outperform rating after meeting with its management. The analyst says the company "sounded confident" about the profile and market opportunity of risdiplam, the continued progress in its lead gene therapy program GT- AADC, and the early development stage signs within its Huntington's program. Abrahams believes that there is still opportunity for share appreciation for PTC Therapeutics.
News For PTCT From the Last 2 Days
There are no results for your query PTCT
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.